Arlt Wiebke, Rosenthal Carmen, Hahner Stefanie, Allolio Bruno
Division of Medical Sciences Institute of Biomedical Research (IBR) Endocrinology and Metabolism, The Medical School, University of Birmingham, Edgbaston, UK.
Clin Endocrinol (Oxf). 2006 Apr;64(4):384-9. doi: 10.1111/j.1365-2265.2006.02473.x.
Evaluation of glucocorticoid replacement quality in adrenal insufficiency (AI) relies primarily on clinical judgement and thus largely depends on the physician's expertise. It is a matter of debate whether cortisol day curves are of value in assessing glucocorticoid replacement quality. Here we compared the results of a structured clinical assessment to the outcome of repeated, timed serum cortisol measurements.
Cross-sectional study in the outpatient department of a university teaching hospital.
Forty-six patients (19 men, 27 women, age range 16-76 years) with primary (n = 23) and secondary (n = 23) AI on stable replacement with a median dose of 37.5 mg cortisone acetate (range 25-50 mg) since 10 +/- 7 years (range 1-31 years).
Clinical performance was scored by structured assessment of signs and symptoms, physical examination and routine biochemical tests. Serum cortisol was measured on two to three separate occasions in three timed samples after the morning glucocorticoid dose. Bone mineral density was measured in 15 patients with long-standing glucocorticoid replacement.
Thirty-seven patients were considered well replaced, whereas clinical scores suggested over- or under-replacement in five and four, respectively. There was no correlation of the clinical score with total or body weight-adjusted glucocorticoid dose. The mean z score of serum cortisol differed significantly between under- and over-replaced patients (P < 0.05) but neither group differed significantly from well-replaced patients. Bone mineral density was normal in all patients studied.
Our results suggest that serum cortisol day curves are of limited value in the monitoring of glucocorticoid replacement. Bone mineral density in AI is generally normal and does not require routine follow-up.
肾上腺皮质功能减退症(AI)患者糖皮质激素替代治疗质量的评估主要依赖临床判断,因此很大程度上取决于医生的专业水平。皮质醇日曲线在评估糖皮质激素替代治疗质量方面是否有价值存在争议。在此,我们将结构化临床评估结果与重复定时血清皮质醇测量结果进行了比较。
在一所大学教学医院的门诊部进行横断面研究。
46例患者(19例男性,27例女性,年龄范围16 - 76岁),其中原发性AI患者23例,继发性AI患者23例,自开始稳定替代治疗以来,醋酸可的松中位剂量为37.5 mg(范围25 - 50 mg),治疗时间为10±7年(范围1 - 31年)。
通过对体征和症状、体格检查及常规生化检查进行结构化评估来对临床表现进行评分。在早晨给予糖皮质激素剂量后,分两到三次在三个定时样本中测量血清皮质醇。对15例长期接受糖皮质激素替代治疗的患者测量骨密度。
37例患者被认为替代治疗良好,而临床评分分别提示5例替代过度和4例替代不足。临床评分与总糖皮质激素剂量或体重调整后的糖皮质激素剂量均无相关性。替代不足和替代过度患者的血清皮质醇平均z评分差异有统计学意义(P < 0.05),但两组与替代良好患者相比差异均无统计学意义。所有研究患者的骨密度均正常。
我们的结果表明,血清皮质醇日曲线在监测糖皮质激素替代治疗方面价值有限。AI患者的骨密度一般正常,无需常规随访。